ERBB2 and cancer: The therapeutic targeting of cancer cells, utilizing approaches such as HER‐2/neu‐directed monoclonal antibodies or FcR‐directed bispecific antibodies,114 has demonstrated how neutrophils participate in the elimination of cancer cells through ADCC.